CMPS options-implied volatility will spike ahead of the two-administration COMP360 topline, with a ≥20% single-session move (either direction) on the release.

Before COMPASS Pathways releases its two-dose psilocybin trial results, the options market — where traders buy contracts to bet on big price moves — will show extreme nervousness. When the results actually drop, the stock price will likely jump or crash by at least 20% in a single trading day. This kind of violent swing is common when a small company's entire future rides on one clinical trial result.

Binary readouts on thin-float psychedelic names produce violent repricing. The setup is textbook; I don't care about ethics, only the volatility structure.